BR9711734A - Controlled-release dosage form of ¬r- (z) alfa-alpha- (metÄxiimino) -alpha- (1-azabicyclo¬2.2.2¾oct-3-yl) acetonitrile monochlorochloride - Google Patents

Controlled-release dosage form of ¬r- (z) alfa-alpha- (metÄxiimino) -alpha- (1-azabicyclo¬2.2.2¾oct-3-yl) acetonitrile monochlorochloride

Info

Publication number
BR9711734A
BR9711734A BR9711734A BR9711734A BR9711734A BR 9711734 A BR9711734 A BR 9711734A BR 9711734 A BR9711734 A BR 9711734A BR 9711734 A BR9711734 A BR 9711734A BR 9711734 A BR9711734 A BR 9711734A
Authority
BR
Brazil
Prior art keywords
alpha
monochlorochloride
metäxiimino
azabicyclo
alfa
Prior art date
Application number
BR9711734A
Other languages
Portuguese (pt)
Inventor
Susan Marie Milosovich
William Muldoon
James Albert Napper
Laurence Rousseau
Joseph Sauer
Original Assignee
Smithkline Beecham Plc
Smithkline Beckman Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc, Smithkline Beckman Corp filed Critical Smithkline Beecham Plc
Publication of BR9711734A publication Critical patent/BR9711734A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
BR9711734A 1996-09-12 1997-09-08 Controlled-release dosage form of ¬r- (z) alfa-alpha- (metÄxiimino) -alpha- (1-azabicyclo¬2.2.2¾oct-3-yl) acetonitrile monochlorochloride BR9711734A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9619074.9A GB9619074D0 (en) 1996-09-12 1996-09-12 Composition
PCT/GB1997/002418 WO1998010762A2 (en) 1996-09-12 1997-09-08 Controlled release dosage form of r-(z)-alpha-methoxyimino-alpha-(1-azabicyclo2.2oct-c-yl)acetonitrile monohydrochloride

Publications (1)

Publication Number Publication Date
BR9711734A true BR9711734A (en) 1999-08-24

Family

ID=10799833

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9711734A BR9711734A (en) 1996-09-12 1997-09-08 Controlled-release dosage form of ¬r- (z) alfa-alpha- (metÄxiimino) -alpha- (1-azabicyclo¬2.2.2¾oct-3-yl) acetonitrile monochlorochloride

Country Status (22)

Country Link
EP (1) EP0929301A2 (en)
JP (1) JP2001500150A (en)
KR (1) KR20000036039A (en)
CN (2) CN1235544A (en)
AR (1) AR008176A1 (en)
AU (1) AU724086B2 (en)
BR (1) BR9711734A (en)
CA (1) CA2265661A1 (en)
CO (1) CO5031291A1 (en)
CZ (1) CZ83299A3 (en)
GB (1) GB9619074D0 (en)
HU (1) HUP9904401A3 (en)
ID (1) ID19589A (en)
IL (1) IL128781A0 (en)
MA (1) MA24359A1 (en)
NO (1) NO991194L (en)
NZ (1) NZ334268A (en)
PE (1) PE2499A1 (en)
PL (1) PL332074A1 (en)
TR (1) TR199900505T2 (en)
WO (1) WO1998010762A2 (en)
ZA (1) ZA978133B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775597B1 (en) * 1998-03-04 2001-04-20 Gattefosse Ets Sa ORAL PELLET ADAPTED TO IMPROVE THE BIOAVAILABILITY OF THE ACTIVE SUBSTANCE, METHOD OF MANUFACTURE
KR20010034588A (en) * 1998-03-11 2001-04-25 피터 기딩스 Composition
DE19918325A1 (en) * 1999-04-22 2000-10-26 Euro Celtique Sa Extruded drug dosage form, e.g. granulate for tableting, comprising an active agent in a polysaccharide-containing matrix, giving a release profile which is controllable by extrusion conditions and/or the inclusion of additives
FR2796840B1 (en) 1999-07-26 2003-06-20 Ethypharm Lab Prod Ethiques LOW-DOSE TABLETS AND METHOD OF PREPARATION
US6733781B2 (en) 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
AR040682A1 (en) 2002-07-25 2005-04-13 Pharmacia Corp DOSAGE FORM ONCE A DAY OF PRAMIPEXOL
JP4808612B2 (en) * 2003-04-25 2011-11-02 田辺三菱製薬株式会社 Composition for oral administration containing alkylenedioxybenzene derivative
ES2273271T5 (en) * 2003-05-14 2013-05-21 Aptalis Pharma Limited Composition of controlled release of mechanical stress resistant drug in vivo
US20050142191A1 (en) * 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
JP2005272347A (en) * 2004-03-24 2005-10-06 Ohara Yakuhin Kogyo Kk Method for producing solid preparation
EA200700388A1 (en) * 2004-08-13 2007-08-31 Бёрингер Ингельхайм Интернациональ Гмбх THE COMPOSITION OF PELLETS OF THE PROLONGED SURVENT, CONTAINING PRAMIPEXOL OR ITS PHARMACEUTICALLY ACCEPTABLE SALT, THE WAY OF ITS MANUFACTURE AND ITS APPLICATION
CN101884626A (en) 2004-08-13 2010-11-17 贝林格尔.英格海姆国际有限公司 The prolongation release tablet, the Preparation Method And The Use that comprise pramipexole or its officinal salt
EP1970056A1 (en) * 2007-03-15 2008-09-17 Polichem S.A. Time-specific delayed/pulsatile release dosage forms
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0392803T3 (en) * 1989-04-13 2004-10-18 Beecham Group Plc Hitherto unknown compounds
GB9409718D0 (en) * 1994-05-14 1994-07-06 Smithkline Beecham Plc Novel compounds
GB9421472D0 (en) * 1994-10-25 1994-12-07 Smithkline Beecham Plc Novel methods
AR004178A1 (en) * 1995-07-29 1998-11-04 Smithkline Beecham Plc PROCEDURE FOR THE FORMULATION OF A PHARMACY, A PHARMACEUTICAL COMPOSITION OBTAINABLE THROUGH THIS PROCEDURE AND THE USE OF THE SAME.

Also Published As

Publication number Publication date
NO991194D0 (en) 1999-03-11
JP2001500150A (en) 2001-01-09
PL332074A1 (en) 1999-08-30
GB9619074D0 (en) 1996-10-23
PE2499A1 (en) 1999-03-24
HUP9904401A3 (en) 2001-03-28
ID19589A (en) 1998-07-23
NO991194L (en) 1999-03-11
CO5031291A1 (en) 2001-04-27
WO1998010762A2 (en) 1998-03-19
TR199900505T2 (en) 1999-06-21
WO1998010762A3 (en) 1998-06-04
ZA978133B (en) 1999-04-12
AU724086B2 (en) 2000-09-14
NZ334268A (en) 2000-10-27
HUP9904401A2 (en) 2000-06-28
IL128781A0 (en) 2000-01-31
CN1235544A (en) 1999-11-17
MA24359A1 (en) 1998-07-01
CA2265661A1 (en) 1998-03-19
CZ83299A3 (en) 1999-08-11
KR20000036039A (en) 2000-06-26
AR008176A1 (en) 1999-12-09
AU4128897A (en) 1998-04-02
EP0929301A2 (en) 1999-07-21
CN1446535A (en) 2003-10-08

Similar Documents

Publication Publication Date Title
EE03903B1 (en) Omeprazole dosage form
IS5721A (en) Pyrolo [2,3-dl] pyrimidine compounds
PT1087970E (en) PYRIMIDINE COMPOUNDS 2,3-D | PYRIMIDINE
DE69804995T2 (en) CYCLONE
EE04293B1 (en) Stable lyophilized dosage forms
GB9823101D0 (en) Pharmaceutically active compounds
DK0797991T3 (en) Delayed-release drug formulation
DK0839039T3 (en) Controlled-release paroxetine preparations
DK0891978T3 (en) 5H-thiazole (3,2-a) pyrimidinderivativer
BR9711734A (en) Controlled-release dosage form of ¬r- (z) alfa-alpha- (metÄxiimino) -alpha- (1-azabicyclo¬2.2.2¾oct-3-yl) acetonitrile monochlorochloride
ATE321784T1 (en) PTHRP ANALOGUE
NO20002451D0 (en) Condensed pyrazine compounds
IS4848A (en) Pharmaceutically useful compounds
GB9823102D0 (en) Pharmaceutically active compounds
PT964867E (en) ANTAGONISTS OF THE TAQUICINIMA
ZA977809B (en) New pharmaceutically active compounds.
NO995033D0 (en) 6,7-disubstituted-4-aminopyrido [2,3-D] pyrimidine
IL131617A0 (en) 5,6,7-Trisubstituted-4-aminopyridol ¬2,3-d¾ pyrimidine compounds
ID16434A (en) COMPOUNDS OF 1,4-DIHYDROPIRIDINS
ZA977808B (en) New pharmaceutically active compounds.
DE29700340U1 (en) Swivel castor
DE29710932U1 (en) Shoe lock
FR2762641B1 (en) FURNITURE LOCK
FI973464A0 (en) Foerfarande Foer framstaellning av en ask med lock av en smal traedstam eller -rot
SE9704874D0 (en) New pharmaceutically active compounds

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.